Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
Year: 2021
Type: article
Abstract: Aducanumab (Aduhelm) was recently approved by the US Food and Drug Administration (FDA) for the treatment of Alzheimer disease (AD). The approval of aducanumab is controversial. We address why we support this decision and welcome the availability of aducanumab as an important therapy for patients with early AD.
Source: Neurology
Authors: Stephen Salloway, Jeffrey Cummings
Institutions: University of Nevada, Las Vegas, Brown University, Butler Hospital
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
Awards: G1931537204, Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors, G305086134, Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease, Nevada Exploratory Alzheimer's Disease Research Center (NVEADRC), G4289261452, G7455214855, Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - Resubmission, Arizona Alzheimer's Disease Research Center, Alzheimer's Clinical Trial InnOvatioN (ACTION) Initiative
OpenAlex ID: W3178304290